The suit originated in 2007, and the result of the calculation is due to past damages and an 11 percent royalty for future sales of the product up until 2018. The case will now go in front of the US District Court again for other issues of invalidity and unenforceability.
|
Share this article with your social network, just click below to share now!
|
|
|
2 comments :
nice blog and have lots of stuff here....
http://biotechnolo.blogspot.com
The surgeon involved with Medtronic's Infuse bone graft study has resigned: http://www.newsinferno.com/archives/11835#more-11835
Post a Comment